NASDAQ · RYTM
Healthcare · Biotechnology
$96.77
Down-$5.67 (-5.53%)
Updated Sep 16, 2026, 9:17 AM
SID Score
4.4/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
RYTM closed at $96.77 after 20 trading sessions, down 16.03% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $101.66 | $101.66 | $96.14 | $96.77 | 914.28K |
| Sep 14, 2026 | $105.27 | $105.93 | $101.09 | $102.44 | 789.71K |
| Sep 11, 2026 | $102.96 | $106.57 | $102.245 | $104.71 | 573.72K |
| Sep 10, 2026 | $99.88 | $102.89 | $99.88 | $102.20 | 422.89K |
| Sep 9, 2026 | $100.23 | $101.77 | $99.8325 | $101.06 | 482.25K |
| Sep 8, 2026 | $100.58 | $103.31 | $99.41 | $101.80 | 513.05K |
| Sep 4, 2026 | $103.53 | $105.71 | $101.25 | $102.74 | 466.91K |
| Sep 3, 2026 | $106.08 | $106.08 | $103.9025 | $104.89 | 269.77K |
| Sep 2, 2026 | $105.50 | $108.57 | $103.95 | $105.42 | 455.59K |
| Sep 1, 2026 | $105.79 | $108.43 | $104.09 | $104.74 | 332.05K |
| Aug 31, 2026 | $106.01 | $108.845 | $103.98 | $106.13 | 775.19K |
| Aug 28, 2026 | $110.21 | $114.75 | $107.09 | $107.17 | 441.21K |
| Aug 27, 2026 | $111.21 | $113.97 | $110.0301 | $112.53 | 311.07K |
| Aug 26, 2026 | $113.21 | $114.75 | $111.35 | $111.87 | 358.96K |
| Aug 25, 2026 | $112.73 | $114.07 | $111.79 | $113.35 | 352.46K |
| Aug 24, 2026 | $112.29 | $113.60 | $109.89 | $111.44 | 400.56K |
| Aug 21, 2026 | $109.38 | $112.59 | $106.58 | $110.00 | 523.14K |
| Aug 20, 2026 | $114.51 | $114.605 | $108.7267 | $108.92 | 568.58K |
| Aug 19, 2026 | $118.31 | $118.31 | $115.26 | $115.73 | 669.9K |
| Aug 18, 2026 | $115.25 | $117.16 | $114.325 | $115.25 | 447.06K |
The latest Smart Investors Daily articles mentioning RYTM.
RYTM research
Company profile and research snapshot.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 28, 2026 | Deutsche Bank | Hold | — |
| Aug 7, 2026 | JP Morgan | Overweight | — |
| Aug 5, 2026 | Citizens | Market Outperform | — |
| Aug 5, 2026 | RBC Capital | Outperform | — |
| Aug 5, 2026 | Citigroup | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 11, 2026
Stanley Druckenmiller’s Duquesne Family Office recently filed its 13F for the second quarter. The firm opened new stakes in more than 40 stocks. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) and Definium Therapeutics, Inc. (NASDAQ:DFTX) are the notable ones in the healthcare space. Duquesne bought 203,618 shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) worth $22.6 million. The fund also […]
Yahoo · Sep 10, 2026
-- Real-world data showed reductions in BMI with up to 18 months of setmelanotide therapy in 30 paediatric patients with acquired hypothalamic obesity (HO) in France – -- Phase 3 analyses demonstrated improvements across multiple cardiometabolic risk indices with setmelanotide in acquired HO -- BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare n
Benzinga · Sep 2, 2026
Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 40.53% on an annualized basis producing an average annual return of 51.66%. Currently, Rhythm Pharmaceuticals has a market
Benzinga · Aug 31, 2026
Rhythm Pharmaceuticals (NASDAQ:RYTM) has outperformed the market over the past 5 years by 40.99% on an annualized basis producing an average annual return of 52.06%. Currently, Rhythm Pharmaceuticals has a market
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RYTM.
